TW
CSTL icon

TritonPoint Wealth’s Castle Biosciences CSTL Stock Holding History

TritonPoint Wealth’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-40,777
Closed -$928K – 291
2025
Q3 		$928K Hold
40,777
– – 0.08% 159
2025
Q2 		$833K Sell
40,777
-860
-2% -$15.9K 0.08% 170
2025
Q1 		$834K Sell
41,637
-5,000
-11% -$124K 0.08% 172
2024
Q4 		$1.24M Sell
46,637
-10,000
-18% -$305K 0.11% 136
2024
Q3 		$1.58M Sell
56,637
-13,762
-20% -$350K 0.14% 126
2024
Q2 		$1.53M Sell
70,399
-21,851
-24% -$487K 0.15% 124
2024
Q1 		$2.04M Sell
92,250
-2,106
-2% -$45.8K 0.21% 104
2023
Q4 		$2.04M Buy
+94,356
New +$1.66M 0.2% 107

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

TritonPoint Wealth's CSTL Position: Q4 2025 in Review

TritonPoint Wealth sold out of Castle Biosciences (CSTL) in Q4 2025, closing a stake of 40,777 shares — an estimated $928K sold.

TritonPoint Wealth first reported a position in CSTL in Q4 2023 and held it in 8 quarters. The position peaked at $2.04M in Q1 2024. 194 funds tracked by Wall St. Rank hold CSTL as of Q4 2025.

  • TritonPoint Wealth reported no remaining Castle Biosciences position as of Q4 2025 after selling out during the quarter.
  • TritonPoint Wealth sold 40,777 Castle Biosciences shares in Q4 2025, an estimated $928K.
  • TritonPoint Wealth first reported a position in Castle Biosciences in Q4 2023 and held it in 8 quarters.
  • TritonPoint Wealth's Castle Biosciences position peaked at $2.04M in Q1 2024.
  • 194 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2025.

Based on TritonPoint Wealth's 13F filing for Q4 2025, filed 20 Jan 2026.